Townsquare Capital LLC Boosts Stake in Danaher Co. (NYSE:DHR)

Townsquare Capital LLC boosted its holdings in shares of Danaher Co. (NYSE:DHR - Free Report) by 25.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,466 shares of the conglomerate's stock after acquiring an additional 2,550 shares during the period. Townsquare Capital LLC's holdings in Danaher were worth $3,466,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in DHR. PGGM Investments bought a new stake in Danaher during the first quarter valued at about $459,000. Cetera Investment Advisers boosted its holdings in shares of Danaher by 338.0% in the 1st quarter. Cetera Investment Advisers now owns 122,223 shares of the conglomerate's stock valued at $30,522,000 after buying an additional 94,318 shares in the last quarter. Cetera Advisors LLC grew its position in shares of Danaher by 44.3% in the 1st quarter. Cetera Advisors LLC now owns 27,346 shares of the conglomerate's stock worth $6,829,000 after buying an additional 8,389 shares during the last quarter. Cetera Advisor Networks LLC raised its stake in shares of Danaher by 6.3% during the 1st quarter. Cetera Advisor Networks LLC now owns 72,454 shares of the conglomerate's stock worth $18,093,000 after acquiring an additional 4,266 shares in the last quarter. Finally, EverSource Wealth Advisors LLC lifted its position in Danaher by 5.3% during the first quarter. EverSource Wealth Advisors LLC now owns 1,366 shares of the conglomerate's stock valued at $337,000 after acquiring an additional 69 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company's stock.

Danaher Price Performance

NYSE DHR traded up $0.86 during trading hours on Friday, reaching $239.69. The company's stock had a trading volume of 1,931,402 shares, compared to its average volume of 2,761,275. The firm has a market capitalization of $173.12 billion, a price-to-earnings ratio of 45.77, a P/E/G ratio of 4.39 and a beta of 0.85. Danaher Co. has a 1-year low of $215.68 and a 1-year high of $281.70. The company's 50-day moving average is $254.59 and its two-hundred day moving average is $259.44. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping analysts' consensus estimates of $1.57 by $0.14. The firm had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. Danaher's quarterly revenue was up 3.1% on a year-over-year basis. During the same period in the previous year, the business posted $2.02 earnings per share. On average, equities analysts predict that Danaher Co. will post 7.5 EPS for the current year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.45%. The ex-dividend date was Friday, September 27th. Danaher's dividend payout ratio (DPR) is presently 20.61%.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. TD Cowen lifted their price target on shares of Danaher from $310.00 to $315.00 and gave the stock a "buy" rating in a report on Wednesday, October 23rd. Evercore ISI upped their target price on Danaher from $275.00 to $278.00 and gave the company an "outperform" rating in a research report on Tuesday, October 1st. UBS Group lowered their price target on Danaher from $309.00 to $305.00 and set a "buy" rating for the company in a report on Wednesday, October 23rd. StockNews.com upgraded Danaher from a "hold" rating to a "buy" rating in a research note on Wednesday. Finally, Barclays decreased their price objective on shares of Danaher from $285.00 to $275.00 and set an "equal weight" rating for the company in a research report on Wednesday, October 23rd. Five investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to MarketBeat.com, Danaher presently has a consensus rating of "Moderate Buy" and an average price target of $287.16.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.